| Autor: |
Seraina Netzer, Patricia Chocano-Bedoya, Martin Feller, Camilla Janett-Pellegri, Lea Wildisen, Annina E Büchi, Elisavet Moutzouri, Elena Gonzalez Rodriguez, Tinh-Hai Collet, Rosalinde K E Poortvliet, Vera J C Mc Carthy, Daniel Aeberli, Drahomir Aujesky, Rudi Westendorp, Terence J Quinn, Jacobijn Gussekloo, Patricia M Kearney, Simon Mooijaart, Douglas C Bauer, Nicolas Rodondi |
| Rok vydání: |
2023 |
| Předmět: |
|
| DOI: |
10.48350/178291 |
| Popis: |
Background loss of skeletal muscle function, strength and mass is common in older adults, with important socioeconomic impacts. Subclinical hypothyroidism is common with increasing age and has been associated with reduced muscle strength. Yet, no randomized placebo-controlled trial (RCT) has investigated whether treatment of subclinical hypothyroidism affects muscle function and mass. Methods this is an ancillary study within two RCTs conducted among adults aged ≥65 years with persistent subclinical hypothyroidism (thyrotropin (TSH) 4.60–19.99 mIU/l, normal free thyroxine). Participants received daily levothyroxine with TSH-guided dose adjustment or placebo and mock titration. Primary outcome was gait speed at final visit (median 18 months). Secondary outcomes were handgrip strength at 1-year follow-up and yearly change in muscle mass. Results we included 267 participants from Switzerland and the Netherlands. Mean age was 77.5 years (range 65.1–97.1), 129 (48.3%) were women, and their mean baseline TSH was 6.36 mIU/l (standard deviation [SD] 1.9). At final visit, mean TSH was 3.8 mIU/l (SD 2.3) in the levothyroxine group and 5.1 mIU/l (SD 1.8, P Conclusions in this ancillary analysis of two RCTs, treatment of subclinical hypothyroidism did not affect muscle function, strength and mass in individuals 65 years and older. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
